Larimar Shares Fall, FDA Submission Seen as Next Hurdle
Larimar Therapeutics shares fell 3.36% to $3.45 Friday as investors awaited a planned June start to its rolling FDA application for nomlabofusp, a protein-replacement drug for Friedreich’s ataxia. The company ended March with $200.4 million in cash and projected funding into Q2 2027. Shareholders approved raising authorized common shares to 215 million. The FDA has approved only one other FA treatment to date.
